Global Leukemia Therapeutic Market 2022-2028

Description

List of Tables

Global Leukemia Therapeutic Market Size, Share & Trends Analysis Reportby Type (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia)byTreatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others) ) Forecast 2022-2028

The global leukemia therapeutic market is anticipated to grow at a substantial CAGR of 7.3% during the forecast period. Acute lymphocytic also known as blood cancer begins from an early version of white blood cells in the bone marrow. The term acute means that leukemia can progress very rapidly, and in case if not treated can be fatal in a few months. Cancer treatments have become advanced day by day, by the use of various therapies the demand and focusing on the unmet medical needs are the prominent factor responsible for the growth of the global leukemia therapeutics market. Moreover, increasing expenditure on research and development, rising focus on the superiority of quality of life, higher investment incurred by the government on healthcare, and advancement in pharmacology to enhance the drug development are factors propelling the growth of this market.

The global leukemia therapeutics market is segmented based on type, and treatment type. Based on type the market is bifurcated into acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia. Based on treatment type, the market is sub-segmented intochemotherapy, immunotherapy, targeted therapy, and others..

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America region is anticipated to hold a major share in the global leukemia therapeutics market, due to a large number of patients pool suffering from cancer and the availability of a strong generic drug market in the emerging countries. In addition, manufacturers' interest in expanding to these North American countries, will further fuel the growth in the near future.

The major companies serving the global leukemia therapeutic market are Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb, Cephalon A/S, Daiichi Sankyo, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2021, Novartis announced that the US FDA approved Scemblix(asciminib) for the treatment of chronic myeloid leukemia(CML). The FDA approved this drug for adult patients with Philadelphia chromosome-positive CML in the chronic phase(Ph+CML-CP). Moreover, Scemblix recommends that patients with CML were previously treated with two or more tyrosine kinase inhibitors(TKIs), and reduced mutations at the defective BCR-ABL 1 gene, which is associated with the over-production of leukemic cells.

Research Methodology

The market study of the global leukemia therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, researchpapers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Leukemia Therapeutic Market Research and Analysis by Types

2. GlobalLeukemia Therapeutic Market Research and Analysis by Drug Types

The Report Covers

Comprehensive research methodology of the global leukemia therapeutic market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global leukemia therapeutic market.
Insights about market determinants that are stimulating the global leukemia therapeutic market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: PHM-1301

Category-Pharmaceuticals

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the GlobalLeukemia Therapeutic Market
Recovery Scenario of GlobalLeukemia Therapeutic Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key CompanyAnalysis

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Leukemia Therapeutics Market by Drug Type
- 4.1.1. Acute Myeloid Leukemia (AML)
- 4.1.2. Chronic Myeloid Leukemia (CML)
- 4.1.3. Acute Lymphocytic Leukemia (ALL)
- 4.1.4. Chronic Lymphocytic Leukemia (CLL)
5.2. Global Leukemia Therapeutics Market by Treatment TypeTreatment Type
- 5.2.1. Chemotherapy
- 5.2.2. Immunotherapy
- 5.2.3. Targeted Therapy
- 5.2.4. Other

5.2.4.1.

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. Abbott Laboratories
7.2. Agios Pharmaceuticals
7.3. Astellas Pharma Inc.
7.4. Biogen Inc
7.5. Bristol Myers Squibb
7.6. Cephalon A/S
7.7. Daiichi Sankyo
7.8. Eisai Co. Ltd
7.9. F. Hoffmann-La Roche Ltd
7.10. GSK Plc
7.11. Innate Pharma Sa
7.12. Johnson & Johnson
7.13. Merck KGgaAa (The Merck Group)
7.14. Neomed Management AS
7.15. Novartis
7.16. Pfizer
7.17. Sanofi
7.18. Spectrum Pharmaceuticals Inc.
7.19. Viracta Therapeutics Inc.